



#1

PRESCRIBED

**TKI+IO**

**Combination First Treatment  
for Advanced Kidney Cancer**

CABOMETYX is a TKI (tyrosine kinase inhibitor),  
OPDIVO is an IO (immunotherapy). Based on IQVIA  
BrandImpact data as of September 2025.  
Subject to change without notice.



Getting started  
on CABOMETYX  
**IN ADVANCED  
KIDNEY CANCER**

Patient portrayal

## What is CABOMETYX?

CABOMETYX is a prescription medicine used to treat:

- People with kidney cancer (renal cell carcinoma). CABOMETYX may be used:
  - In combination with nivolumab to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC), and you have not already had treatment for your advanced RCC.
  - Alone to treat people with advanced RCC.

It is not known if CABOMETYX is safe and effective in children.

## SELECT IMPORTANT SAFETY INFORMATION

### What are the possible side effects of CABOMETYX?

**CABOMETYX may cause serious side effects, including bleeding (hemorrhage).**

CABOMETYX can cause severe bleeding that may lead to death. Tell your healthcare provider right away if you get any signs of bleeding during treatment with CABOMETYX, including: coughing up blood or blood clots; vomiting blood or if your vomit looks like coffee grounds; red or black (looks like tar) stools; menstrual bleeding that is heavier than normal; and any unusual or heavy bleeding.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

# Learn more about your prescribed treatment

Welcome! Here you can learn more about CABOMETYX, a medicine used to treat advanced kidney cancer (renal cell carcinoma) that has spread.

You may have been prescribed CABOMETYX alone or in combination with a medicine called OPDIVO® (nivolumab) if you have not already had treatment.

## Remember



Always talk to your healthcare team if you have any questions or concerns.



[Tap here](#) to visit CABOMETYX.com for more information and helpful resources.



The information in this handbook is not a substitute for advice from your healthcare team.

## SELECT IMPORTANT SAFETY INFORMATION

**A tear in your stomach or intestinal wall (perforation) or an abnormal connection between 2 parts of your body (fistula).** Tell your healthcare provider right away if you get tenderness or pain in your stomach area (abdomen) that is severe or that does not go away.

**Blood clots, stroke, heart attack, and chest pain.** Get emergency help right away for:

- swelling or pain in your arms or legs
- shortness of breath
- feel lightheaded or faint
- sweating more than usual
- numbness or weakness of your face, arm, or leg, especially on one side of your body
- sudden confusion, trouble speaking or understanding
- sudden trouble seeing in one or both eyes
- sudden trouble walking
- dizziness, loss of balance or coordination
- a sudden severe headache

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

## How CABOMETYX may work

p. 4

## Looking at the CABOMETYX clinical studies

 +  as a combination treatment

p. 8

 alone

p. 16

## Taking your CABOMETYX

p. 18

## Important Safety Information

p. 22

## Working with your healthcare team to help manage certain side effects

p. 26

## Accessing financial support information and resources



p. 28



for free educational resources for your treatment journey



p. 30

OPDIVO® and the related logo are registered trademarks and OPDIVO Qvantig™ and the related logo are trademarks of Bristol-Myers Squibb Company.



# How CABOMETYX (cabozantinib) may work

CABOMETYX is a kind of medicine called a tyrosine kinase inhibitor (TKI). OPDIVO® (nivolumab) is a kind of medicine called an immunotherapy.

These 2 medicines may be prescribed together and work differently to treat advanced kidney cancer.

### The following pages show:

- What happens in advanced kidney cancer
- How CABOMETYX may work alone
- How CABOMETYX may work with OPDIVO. The 2 treatments work differently

### Key



protein



immunosuppressive cells



immune cells



OPDIVO



CABOMETYX

See  
**CABOMETYX**  
in action




 **TAP  
HERE**

## What happens in cancer


Your body's cells include proteins that send signals telling cells to grow and divide.




In cancer, these signals cause blood vessels to grow and feed the tumor (angiogenesis).




The immune cells that usually help find and kill cancer cells are stopped by immunosuppressive cells.



## How CABOMETYX (cabozantinib) may work alone



CABOMETYX is believed to reduce or slow the proteins' signals that tell cancer cells to grow and divide.



CABOMETYX may limit the growth of blood vessels that feed the tumor. It also may help the body kill cancer cells.




With CABOMETYX, tumors may stop growing.

## How CABOMETYX may work in combination with OPDIVO® (nivolumab)


Sometimes CABOMETYX is given with an immunotherapy medicine called OPDIVO.



OPDIVO helps immune cells identify and attack cancer cells that are hiding.



CABOMETYX + OPDIVO may help improve your body's ability to fight advanced kidney cancer.



### Key

-   
protein
-   
immune cells
-   
CABOMETYX
-   
immunosuppressive cells
-   
OPDIVO

Treatment with CABOMETYX alone or in combination with OPDIVO may impact both cancer and normal cells—which may result in certain side effects. For more information about CABOMETYX side effects, please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information. For more information on OPDIVO, including potential side effects, please visit [OPDIVO.com](http://OPDIVO.com).




If you have advanced or Stage 4 kidney cancer that hasn't been treated, CABOMETYX could help.

CABOMETYX was tested and evaluated as a first treatment in a clinical study.

The CABOMETYX clinical study enrolled people with kidney cancer that had spread beyond the kidney into other areas of the body. This would be their first treatment, also known as first-line treatment.



OR sunitinib\* by tablet



The combination of CABOMETYX and OPDIVO is a **dual approach** to treatment.

- CABOMETYX is a tyrosine kinase inhibitor, or TKI
- OPDIVO is an immunotherapy, or IO

**SELECT IMPORTANT SAFETY INFORMATION**

**High blood pressure (hypertension).** Hypertension is common with CABOMETYX and sometimes can be severe. Your healthcare provider will check your blood pressure before starting CABOMETYX and regularly during treatment with CABOMETYX. If needed, your healthcare provider may prescribe medicine to treat your high blood pressure. Tell your healthcare provider if you develop severe headaches, nose bleeds, tiredness or confusion, vision changes, chest pain, trouble breathing, irregular heartbeat, or blood in your urine.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

A total of 651 people participated in the clinical study and were split into 2 groups:

323 took CABOMETYX and OPDIVO

328 took sunitinib

People stayed on treatment until their tumors started to grow, or they had a side effect that could not be managed.

Here are 2 analyses of the clinical study at different time points:

The first analysis was done to support approval of CABOMETYX + OPDIVO as a combination treatment for people with advanced kidney cancer who have not had prior treatment.

This clinical study looked at people's results at a median<sup>†</sup> of 18.1 months follow-up, or **1½ years.**

A later analysis, which is typical for clinical studies, looked at people's numbers at a median<sup>†</sup> of 67.6 months follow-up, or **5½ years.**

The follow-up analysis was not based on the same type of testing as the first analysis and should not be considered definitive.

\*Sunitinib is a prescription medicine used to treat adults with advanced kidney cancer.  
†Median is the middle value in a set of measurements — for some, it was shorter; for others, longer.

Proven results at 1½ years:

On average, people taking CABOMETYX + OPDIVO went longer without tumors growing or spreading

People were able to  
**LIVE WITHOUT  
TUMOR GROWTH  
2x LONGER**

Median\* of **16.6** months for CABOMETYX vs **8.3** months for sunitinib (based on people's results at a median\* of 18.1 months follow-up)

Individual results may vary.

Follow-up analysis at 5½ years:

Average number of months people went without tumors growing or spreading

Median\* of  
**16.4** months for CABOMETYX + OPDIVO  
**8.3** months for sunitinib  
(based on people's results at a median\* of 67.6 months follow-up)

Please consider that the follow-up analysis was not based on the same type of testing as the 1½-year analysis and is not definitive; individual results may vary.

\*Median is the middle value in a set of measurements — for some, it was shorter; for others, longer.

### SELECT IMPORTANT SAFETY INFORMATION

**Heart problems.** CABOMETYX can cause heart failure that may lead to death. Your healthcare provider may check your heart function before and during treatment with CABOMETYX. Tell your healthcare provider right away if you get any of the following signs and symptoms: feeling like your heart is pounding, racing, or beating irregularly; shortness of breath; swelling of your ankles or feet; feeling lightheaded; feeling tired.

**Diarrhea.** Diarrhea is common with CABOMETYX and can be severe. If needed, your healthcare provider may prescribe medicine to treat your diarrhea. Tell your healthcare provider right away if you have frequent loose, watery bowel movements.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

Proven results at **1½ years**:

**CABOMETYX + OPDIVO reduced the risk of dying by 40% vs sunitinib. At the time the study was analyzed, the median\* survival time for both treatments was still unknown because many people were still living.†**

Individual results may vary.

Follow-up analysis at **5½ years**:

**Average number of months people lived**

**46.5** months for CABOMETYX + OPDIVO  
**35.5** months for sunitinib  
**Median\* Overall Survival**

**Percent of people alive at 5 years**

**41%** for CABOMETYX + OPDIVO  
**35%** for sunitinib

Please consider that the follow-up analysis was not based on the same type of testing as the 1½-year analysis and is not definitive; individual results may vary.

\*Median is the middle value in a set of measurements — for some, it was shorter, for others, longer.

†In the preplanned final analysis, median overall survival was 37.7 months for CABOMETYX + OPDIVO and 34.3 months for sunitinib (based on people's results at a median\* of 32.9 months follow-up).

Cabozantinib + nivolumab is a **preferred first-line treatment option** for certain people with advanced clear-cell or non-clear-cell kidney cancer (RCC) by a nonprofit group of leading U.S. cancer centers<sup>‡</sup>

<sup>‡</sup>The group is known as the National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) and is dedicated to improving and facilitating quality, effective, equitable, and accessible care. Preferred interventions are interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Kidney Cancer V1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 15, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

### SELECT IMPORTANT SAFETY INFORMATION

**Liver problems.** Liver problems may happen during treatment with CABOMETYX. When CABOMETYX is taken in combination with nivolumab, severe changes in liver function tests may happen more often than if you take CABOMETYX alone. Your healthcare provider will do blood tests to check your liver function before and during treatment with CABOMETYX.

Tell your healthcare provider right away if you develop symptoms of liver problems including: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, bleeding or bruising more easily than normal.

**A skin problem called hand-foot skin reaction.** Hand-foot skin reactions are common with CABOMETYX and can be severe. Tell your healthcare provider right away if you have rashes, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

Proven results at 1½ years:

**TUMORS SHRUNK  
IN SIZE IN**

**2x**

**AS MANY PEOPLE**

**55.7%** CABOMETYX + OPDIVO  
vs **27.1%** sunitinib  
(complete + partial responses)

**TUMORS DISAPPEARED  
COMPLETELY IN ALMOST**

**2x**

**AS MANY PEOPLE**

**8%** CABOMETYX + OPDIVO  
vs **4.6%** sunitinib  
(complete response)

Individual results may vary.

Study results at 1½ years:

**Percent of people with tumors that stabilized or shrunk**

**88%**  
of people taking  
CABOMETYX + OPDIVO  
**32.2%** stabilized and  
**55.7%** shrunk

**vs**

**69%**  
of people taking  
sunitinib  
**42.1%** stabilized and  
**27.1%** shrunk

**5.6%** of people progressed with CABOMETYX + OPDIVO vs  
**13.7%** of people with sunitinib

Please consider that this analysis is not definitive and individual results may vary.

**SELECT IMPORTANT SAFETY INFORMATION**

**Adrenal gland problems.** Your healthcare provider will monitor you for this problem. Your healthcare provider may prescribe hormone replacement therapy or corticosteroid medicines if needed. Tell your healthcare provider right away if you develop any of the following signs or symptoms: extreme tiredness, dizziness or fainting, weakness, nausea, or vomiting.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

Follow-up analysis at 5½ years:

**Percent of people with tumors that shrunk in size**

**55.7%** for CABOMETYX + OPDIVO  
**27.4%** for sunitinib  
(complete + partial responses)

**Percent of people with tumors that disappeared completely**

**13.9%** for CABOMETYX + OPDIVO  
**4.6%** for sunitinib  
(complete response)

Follow-up analysis at 5½ years:

**Percent of people with tumors that stabilized or shrunk**

**88%**  
of people taking  
CABOMETYX + OPDIVO  
**32.2%** stabilized and  
**55.7%** shrunk

**vs**

**69%**  
of people taking  
sunitinib  
**41.5%** stabilized and  
**27.4%** shrunk

**6.5%** of people progressed with CABOMETYX + OPDIVO vs  
**14.3%** of people with sunitinib

Please consider that the follow-up analysis was not based on the same type of testing as the 1½-year analysis and is not definitive; individual results may vary.

**Disappeared completely** is known as a complete response and means the disappearance of signs of cancer in response to treatment; this does not necessarily mean the cancer has been cured. **Stabilized** (stable disease) means that changes in tumor sizes were too small to be reported as growing or shrinking. This may be due to how tumors behave naturally rather than any effect of the medicine.

**Partial response** is a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.



## Proven results of CABOMETYX (cabozantinib) alone

### For people who have been treated before:

A clinical study enrolled adults with advanced kidney cancer who had received at least 1 prior treatment: 330 were given CABOMETYX and 328 were given everolimus.\*

People stayed on treatment until their tumors started to grow or they had a side effect that could not be managed.

### The study results showed:

On average, people taking CABOMETYX went longer without tumors growing or spreading

People were able to  
**LIVE WITHOUT TUMOR GROWTH ALMOST 2x LONGER**

Median of **7.4** months for CABOMETYX vs **3.8** months for everolimus

Individual results may vary.

### SELECT IMPORTANT SAFETY INFORMATION

**Severe jaw bone problems (osteonecrosis).** Your healthcare provider should examine your mouth before you start and during treatment with CABOMETYX. Tell your dentist that you are taking CABOMETYX. It is important for you to practice good mouth care during treatment with CABOMETYX. Tell your healthcare provider right away if you develop any symptoms of jaw problems, including: jaw pain, toothache, or sores on your gums.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

On average, people taking CABOMETYX had increased survival

People were more likely to  
**LIVE LONGER**

Median<sup>†</sup> of **21.4** months for CABOMETYX vs **16.5** months for everolimus

People taking CABOMETYX had a greater rate of tumor reduction

TUMORS SHRUNK IN SIZE FOR  
**5x**  
MORE PEOPLE

**17%** for CABOMETYX vs **3%** for everolimus. In the clinical study, the tumor had to shrink by at least 30% and had to be confirmed by a second scan

\*Everolimus is a prescription medicine used to treat adults with advanced kidney cancer when certain other medicines have not worked.

<sup>†</sup>Median is the middle value in a set of measurements—for some it was shorter; for others, longer.

## CABOMETYX (cabozantinib) dosing

CABOMETYX is a **non-chemotherapy tablet** you can take at home **once-daily, or as directed**

Take CABOMETYX as prescribed by your doctor. Do not stop taking any medicine without direction from your doctor.

### The recommended starting dosages

If you take **CABOMETYX in combination with OPDIVO®** (nivolumab) or **OPDIVO Qvantig™** (nivolumab+hyaluronidase-nvhy)

Ask your healthcare team which OPDIVO administration option may be right for you



**CABOMETYX**  
tablet  
40 mg once daily

+

**OPDIVO**  
infusion/IV  
every 2 weeks  
or  
every 4 weeks

or



**CABOMETYX**  
tablet  
40 mg once daily

+

**OPDIVO Qvantig**  
injection  
every 2 weeks  
or  
every 4 weeks

### If you are taking CABOMETYX alone

 **CABOMETYX** tablet 60 mg once daily

Your doctor or nurse will determine the dose that is right for you

Dose adjustments are common and happened in the **clinical study that showed the effectiveness and safety of CABOMETYX**

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

## Each person who takes CABOMETYX may respond differently

Not everyone will stay on the same dose of CABOMETYX. Finding the right dose for you may help keep you on treatment.

Your healthcare team will partner with you to find a balance between efficacy and managing side effects



Your dose may be adjusted based on how your body responds to the medicine



Dose adjustments are not setbacks, since they may help you stay on treatment



Dose reductions are a way to customize treatment according to your needs

Watch actual healthcare professionals explain why dose adjustments are common during treatment



 **TAP HERE**

Talk to your healthcare team to learn ways to help manage certain side effects, either through lifestyle changes or with medicines they recommend.

Please note that not all side effects can be managed, and some may lead to permanent discontinuation of the medicine.

# How to take CABOMETYX (cabozantinib)

## DO



- Swallow your CABOMETYX tablets whole
- Take your CABOMETYX dose at the same time everyday, or as prescribed
- Take CABOMETYX on an empty stomach; take CABOMETYX at least 1 hour before or at least 2 hours after eating

## DO NOT



- Take CABOMETYX with food
- Crush, chew, or split the tablet



- **Drink grapefruit juice, eat grapefruit, or take supplements that contain grapefruit or St. John's wort** during treatment with CABOMETYX

Tell your healthcare team about all the medicines you take, including prescription or over-the-counter medicines, vitamins, and herbal supplements.

**Call your doctor or nurse right away** if you take too much CABOMETYX

## What if you forget to take your CABOMETYX?

If your next dose is in:

### Less than 12 hours


- Do not make up the missed dose
- Take the next dose when you usually take it

### 12 hours or more

- Talk to your doctor or nurse if you miss a dose

This is not intended as medical advice. Talk to your doctor if you have questions.

Watch actual patients share their experiences, including tips on how to remember to take CABOMETYX



 **TAP  
HERE**

## Indication and Important Safety Information

### What is CABOMETYX?

CABOMETYX is a prescription medicine used to treat:

- People with kidney cancer (renal cell carcinoma). CABOMETYX may be used:
  - In combination with nivolumab to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC), and you have not already had treatment for your advanced RCC
  - Alone to treat people with advanced RCC.

It is not known if CABOMETYX is safe and effective in children.

### What are the possible side effects of CABOMETYX?

**CABOMETYX may cause serious side effects, including:**

**Bleeding (hemorrhage).** CABOMETYX can cause severe bleeding that may lead to death. Tell your healthcare provider right away if you get any signs of bleeding during treatment with CABOMETYX, including:

- coughing up blood or blood clots
- vomiting blood or if your vomit looks like coffee grounds
- red or black (looks like tar) stools
- menstrual bleeding that is heavier than normal
- any unusual or heavy bleeding

**A tear in your stomach or intestinal wall (perforation) or an abnormal connection between 2 parts of your body (fistula).** Tell your healthcare provider right away if you get tenderness or pain in your stomach area (abdomen) that is severe or that does not go away.

**Blood clots, stroke, heart attack, and chest pain.** Get emergency help right away for:

- swelling or pain in your arms or legs
- shortness of breath
- feel lightheaded or faint
- sweating more than usual
- numbness or weakness of your face, arm, or leg, especially on one side of your body
- sudden confusion, trouble speaking or understanding
- sudden trouble seeing in one or both eyes
- sudden trouble walking
- dizziness, loss of balance or coordination
- a sudden severe headache

**High blood pressure (hypertension).** Hypertension is common with CABOMETYX and sometimes can be severe. Your healthcare provider will check your blood pressure before starting CABOMETYX and regularly during treatment with CABOMETYX. If needed, your healthcare provider may prescribe medicine to treat your high blood pressure. Tell your healthcare provider if you develop severe headaches, nose bleeds, tiredness or confusion, vision changes, chest pain, trouble breathing, irregular heartbeat, or blood in your urine.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

**Heart problems.** CABOMETYX can cause heart failure that may lead to death. Your healthcare provider may check your heart function before and during treatment with CABOMETYX. Tell your healthcare provider right away if you get any of the following signs and symptoms: feeling like your heart is pounding, racing, or beating irregularly; shortness of breath; swelling of your ankles or feet; feeling lightheaded; feeling tired.

**Diarrhea.** Diarrhea is common with CABOMETYX and can be severe. If needed, your healthcare provider may prescribe medicine to treat your diarrhea. Tell your healthcare provider right away if you have frequent loose, watery bowel movements.

**A skin problem called hand-foot skin reaction.** Hand-foot skin reactions are common with CABOMETYX and can be severe. Tell your healthcare provider right away if you have rashes, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.

**Liver problems.** Liver problems may happen during treatment with CABOMETYX. When CABOMETYX is taken in combination with nivolumab, severe changes in liver function tests may happen more often than if you take CABOMETYX alone. Your healthcare provider will do blood tests to check your liver function before and during treatment with CABOMETYX. Tell your healthcare provider right away if you develop symptoms of liver problems including: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, bleeding or bruising more easily than normal.

**Adrenal gland problems.** Your healthcare provider will monitor you for this problem. Your healthcare provider may prescribe hormone replacement therapy or corticosteroid medicines if needed. Tell your healthcare provider right away if you develop any of the following signs or symptoms: extreme tiredness, dizziness or fainting, weakness, nausea, or vomiting.

**Protein in your urine and possible kidney problems.** Symptoms may include swelling in your hands, arms, legs, or feet. Your healthcare provider will check you for this problem during treatment with CABOMETYX.

**Severe jaw bone problems (osteonecrosis).** Your healthcare provider should examine your mouth before you start and during treatment with CABOMETYX. Tell your dentist that you are taking CABOMETYX. It is important for you to practice good mouth care during treatment with CABOMETYX. Tell your healthcare provider right away if you develop any symptoms of jaw problems, including: jaw pain, toothache, or sores on your gums.

## Important Safety Information

(Cont'd)

**Wound healing problems.** Wound healing problems have happened in people who take CABOMETYX. Tell your healthcare provider if you plan to have any surgery before or during treatment with CABOMETYX.

- You should stop taking CABOMETYX at least 3 weeks before planned surgery.
- Your healthcare provider should tell you when you may start taking CABOMETYX again after surgery.

**Reversible posterior leukoencephalopathy syndrome (RPLS).** A condition called reversible posterior leukoencephalopathy syndrome can happen during treatment with CABOMETYX. Tell your healthcare provider right away if you have headaches, seizures, confusion, changes in vision, or problems thinking.

**Change in thyroid function.** CABOMETYX can cause changes in your thyroid function, including changes to thyroid hormone levels in your blood. Your healthcare provider will do blood tests to check your thyroid function before and during treatment with CABOMETYX.

**Decreased calcium level in your blood (hypocalcemia).** CABOMETYX can cause you to have a decreased amount of calcium in your blood. Your healthcare provider will do blood tests to check you for this problem and give you calcium if needed. **Tell your healthcare provider right away if you get any of the following signs or symptoms:**

- muscle stiffness or muscle spasms
- numbness or tingling in your fingers, toes, or around your mouth
- seizures
- sudden weight gain
- swelling of your arms, hands, legs, and ankles

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with CABOMETYX if you have certain side effects.

**The most common side effects of CABOMETYX include:**

- tiredness
- nausea and vomiting
- constipation
- decreased appetite
- weight loss

**The most common side effects of CABOMETYX when used with nivolumab include:**

- tiredness
- mouth sores
- rash
- low thyroid hormone levels (hypothyroidism)
- pain in muscles, bones, and joints
- decreased appetite
- nausea
- changes in the way things taste
- stomach-area (abdominal) pain
- cough
- upper respiratory tract infection

CABOMETYX may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

These are not all of the possible side effects of CABOMETYX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

If your healthcare provider prescribes CABOMETYX in combination with nivolumab, also read the Medication Guide that comes with nivolumab.

**Before you take CABOMETYX,** tell your healthcare provider about all of your medical conditions, including if you:

- have had a liver problem other than liver cancer.
- have a recent history of bleeding, including coughing up or vomiting blood, or black tarry stools.
- have an open or healing wound.
- have high blood pressure.
- have a low calcium level in your blood (hypocalcemia).
- plan to have any surgery, dental procedure, or have had a recent surgery. You should stop treatment with CABOMETYX at least 3 weeks before planned surgery.
- are pregnant, or plan to become pregnant. CABOMETYX can harm your unborn baby.
  - If you are able to become pregnant, your healthcare provider will check your pregnancy status before you start treatment with CABOMETYX.
  - Females who are able to become pregnant should use effective birth control (contraception) during treatment and for 4 months after your last dose of CABOMETYX.
  - Talk to your healthcare provider about birth control methods that may be right for you.
  - If you become pregnant or think you are pregnant, tell your healthcare provider right away.
- are breastfeeding or plan to breastfeed. It is not known if CABOMETYX passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of CABOMETYX.

**Tell your healthcare provider about all the medicines you take,** including prescription or over-the-counter medicines, vitamins, and herbal supplements. CABOMETYX and certain other medicines may affect each other, causing side effects.

**What should I avoid while taking CABOMETYX?**


**Avoid** drinking grapefruit juice, eating grapefruit, or taking supplements that contain grapefruit or St. John's wort during treatment with CABOMETYX.



## Working with your healthcare team to help manage certain side effects

CABOMETYX can cause certain side effects. The sooner you share information, the sooner your healthcare team can help you manage certain side effects.

We have an approach called **AIM** to help you share your side effects with your healthcare team



Side effects can happen at any time, including in the first weeks or months after starting treatment with CABOMETYX.

### SELECT IMPORTANT SAFETY INFORMATION

**Reversible posterior leukoencephalopathy syndrome (RPLS).** A condition called reversible posterior leukoencephalopathy syndrome can happen during treatment with CABOMETYX. Tell your healthcare provider right away if you have headaches, seizures, confusion, changes in vision, or problems thinking.

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

Your healthcare team members know you and are experts on managing your condition — but they can't do it without **you**.



**Contact your team immediately** with any questions or concerns.



**Take an active role** by knowing who you should contact and how you should contact them to get your questions or concerns addressed.

The sooner they know about your concerns, the sooner they can help



Your primary contact may be your oncologist or nurse.

Ask them which team member's expertise can help you and then actively work with them to address any issues or find additional support that may be available to you.

Other team members may include:

- nurse navigator
- social worker
- patient navigator
- pharmacist
- psychiatrist
- nutritionist
- home health aide

# Financial support information and resources



To learn more about how EASE can help you, contact us at:

**1-844-900-EASE**  
**(1-844-900-3273)**

Exelixis Access Services (EASE) is your resource for questions and needs related to insurance coverage, financial assistance, and treatment support for CABOMETYX® (cabozantinib).

## Helping You Start and Stay on CABOMETYX

Your EASE Case Manager is available by phone to help you:

- Understand if your health insurance covers CABOMETYX tablets and what your out-of-pocket costs for CABOMETYX may be
- Learn about your financial support options

 **TAP HERE** to sign up or get more information about EASE

### If you are commercially insured...

#### **EASE Co-pay Program**

Eligible, commercially insured patients may pay as little as \$0 per month. Annual and transaction limits apply. The EASE Co-Pay Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs or where prohibited by law. Additional Terms and Conditions apply.

### If you are uninsured or cannot afford your medicine...


#### **EASE Patient Assistance Program**

May provide you with CABOMETYX free of charge if you qualify. Additional restrictions and eligibility rules apply.

This description of the Exelixis® Access Services program is for informational purposes only. Exelixis makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.

## Access. Assistance. Along the journey.

 **CALL: 1-844-900-EASE**  
**(1-844-900-3273)**

 **Monday to Friday**  
**8:00 AM to 8:00 PM (ET)**

## Get support for your treatment journey

The BE CONNECTED support program is designed to offer educational information for you or someone you are caring for who is taking CABOMETYX. You can learn more about what you may expect while on treatment with CABOMETYX.

- Recognizing side effects and working with your healthcare team to help manage them
- Where to find useful resources
- Lifestyle tips offering wellness support
- Information about organizations that may offer support

**For questions about treatment, please speak with your healthcare team.**

Please see Important Safety Information on pages 22-25 and [tap here](#) for the Patient Information in the full Prescribing Information.

